linjc16/ctgov huggingface dataset:
the Value of Transanal Endoscopic ISR

Study Overview
=================
Brief Summary
-----------------
The Intersphincteric resection (ISR) technique is an alternative for anal preservation in ultra-low rectal cancer. The transanal total mesorectal excision (TaTME) technique might compensate for the deficiencies of ISR in terms of tumor spillage and poor surgical field exposure. Thus, we decided to perform ISR through a transanal endoscopic approach (taE-ISR), seeking to evaluate the value of this innovative technique in extreme anal preservation in ultra-low rectal cancer.

Official Title
-----------------
The Value of Transanal Endoscopic Intersphincteric Resection (taE-ISR) in Extreme Anal Preservation in Ultra-low Rectal Cancer

Conditions
-----------------
Rectal Cancer

Intervention / Treatment
-----------------
* Procedure: transanal endoscopic ISR


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Age between 18 and 75 years American Society of Anesthesiologists (ASA) score I to III A biopsy proven histological diagnosis of rectal carcinoma MR Rectal examination confirmed the preoperative stage as (y) cT1-3N0-2M0 Preoperative digital examination, colonoscopy and imaging examination confirmed that the lower margin of the tumor was less than 5cm from the anus Preoperative digital examination, colonoscopy and imaging examination confirmed the tumor diameter ≤5cm Exclusion Criteria: Pregnant or lactating women Synchronous rectal carcinoma History of colorectal cancer or other malignant tumors Clinical evidence of metastasis Emergency procedure

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 80 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| transanal endoscopic ISR<br> | Procedure: transanal endoscopic ISR<br>* perform ISR using laparoscopy through transanal port<br>|
| traditional ISR<br> | |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| anal preservation rate | No conversion to APR and closure was closed within 1 year after surgery | 1 year after sugery | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| incidence of Defecation disorders | A Wexner score >10 indicated the existence of defecation dysfunction | 6 months after surgery | 
| incidence of positive distal resection margin | A positive distal resection margin (DRM) was diagnosed with the presence of tumor cells within 1mm from the DRM | 30 days after surgery |
Articaine Efficiency in Pulpectomy of Children With Irreversible Pulpitis Under the Age of Four

Study Overview
=================
Brief Summary
-----------------
A two-tailed randomized controlled trial with two parallel arms is aimed to compare success proportions of the articaine and lidocaine groups in children with irreversible pulpitis under 4 years. The participants will be randomly assigned into two equal groups (82 children per group): the control group will receive lidocaine and the intervention group will receive the articaine local anesthesia. The direct observation tool FLACC was considered to assess pain severity. The behavior was assessed during pulpectomy procedures using the Frankl behavior rating scale (FBRS)

Official Title
-----------------
Articaine Success in Pulpectomy of Primary Molars With Irreversible Pulpitis in Children Under Four Years: a Randomized Controlled Trial

Conditions
-----------------
Dental Pulp Diseases

Intervention / Treatment
-----------------
* Drug: articaine hydrochloride 4% with epinephrine 1:100 000
* Drug: Lidocaine hydrochloride 2% with epinephrine 1:100 000


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Healthy 36-47 month-children (ASA class I or II) weighing at least 15 kilograms Children should be intellectually fit, and cooperative, with no behavior or communication abnormalities Presence of a carious maxillary or mandibular second primary molars with signs and symptoms of irreversible pulpitis Exclusion Criteria: Molars with unrestorable crowns Molars with necrotic pulps, pathological mobility, gingival swelling or abscess, fistulous or sinus tract, or apical periodontitis

Ages Eligible for Study
-----------------
Minimum Age: 36 Months
Maximum Age: 47 Months

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Other
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Quadruple


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: Articaine<br> | Drug: articaine hydrochloride 4% with epinephrine 1:100 000<br>* Local anesthetic agent<br>Drug: Lidocaine hydrochloride 2% with epinephrine 1:100 000<br>* Local anesthetic agent<br>|
| Active Comparator: Lidocaine<br> | Drug: articaine hydrochloride 4% with epinephrine 1:100 000<br>* Local anesthetic agent<br>Drug: Lidocaine hydrochloride 2% with epinephrine 1:100 000<br>* Local anesthetic agent<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Face, Legs, Activity, Cry, Consolability pain scale | its scores range from None/mild pain scores 0-3 Moderate pain scores 4-6 Severe pain scores 7-10 | up to 24 hours |
Feasibility Clinical Evaluation of the Calibreye System

Study Overview
=================
Brief Summary
-----------------
To evaluate the safety and feasibility of the Calibreye System in patients with open angle glaucoma.

Detailed Description
-----------------
This is a prospective, nonrandomized, open-label feasibility clinical trial, to evaluate the surgical procedure, safety and effectiveness of the Calibreye System in reducing intraocular pressure in subjects with open angle glaucoma.

Official Title
-----------------
Feasibility Clinical Evaluation of the Calibreye System

Conditions
-----------------
Glaucoma, Open-Angle

Intervention / Treatment
-----------------
* Device: Calibreye System


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Open angle, pseudoexfoliative or pigmentary glaucoma IOP at preoperative visit of ≥ 18mmHg and ≤ 45mmHg Visual field mean deviation score of -3dB or worse Area of healthy, free and mobile conjunctiva in the target quadrant Shaffer angle grade ≥ 3 in the target quadrant Exclusion Criteria: Angle closure glaucoma Congenital, neovascular or other secondary glaucomas Previous intraocular surgery (with the exception of laser trabeculoplasty or uncomplicated phacoemulsification with IOL occurring > 3 months prior to the preoperative visit) Previous glaucoma shunt/valve in the target quadrant Clinically significant inflammation or infection in the study eye within 30 days prior to the preoperative visit History of corneal surgery, corneal opacities or corneal disease Active diabetic retinopathy

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Intervention Model: Single Group Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: Investigational Device Arm<br>Subjects will receive a Calibreye glaucoma device (permanent implant) | Device: Calibreye System<br>* Implantation of a glaucoma device to reduce intraocular pressure<br>* Other names: Glaucoma device, Glaucoma implant, Aqueous Shunt;|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Intraocular Pressure | Percent change in IOP from baseline to the 12-month visit | 12 Months | 
| Adverse Events | Number and percentage of subjects having any adverse event | 12 Months | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Glaucoma Medication Usage | Change in number of medications used compared to baseline | 12 Months |
Study of Anxiety After a Session of Energy Resonance by Cutaneous Stimulation

Study Overview
=================
Brief Summary
-----------------
Performing a breast macrobiopsy can be extremely delicate and anxiety-provoking. It can have an impact on the course of future examinations. Patients' emotional feelings also have a definite impact on the nursing staff. The purpose of the MBRESC study is to evaluate Energy Resonance by Cutaneous Stimulation , a manual acupressure technique, in the management of anxiety prior to breast macrobiopsy.

Official Title
-----------------
Study of the Reduction of Anxiety After a Session of Energy Resonance by Cutaneous Stimulation in the Management of Patients Requiring Breast Macrobiopsy.

Conditions
-----------------
Breast Neoplasm

Intervention / Treatment
-----------------
* Other: Energy Resonance by Cutaneous Stimulation


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Patient has received full information on the organization and purpose of the research, and has signed an informed consent form. Patient over 18 years of age Patient undergoing a diagnostic breast macrobiopsy for suspected breast cancer Patient undergoing a macro breast biopsy for the first time Patient affiliated to or benefiting from a social security schem Exclusion Criteria: Patient with a history of breast cancer or other pathologies requiring invasive procedures Patient with several lesions to be biopsied Patient with psychiatric pathology Patient under anxiolytic or psychotropic treatment initiated in the month before the breast macrobiopsy

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Supportive Care
Intervention Model: Single Group Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: Energy Resonance by Cutaneous Stimulation<br>one Energy Resonance by Cutaneous Stimulation session performed before macrobiopsy | Other: Energy Resonance by Cutaneous Stimulation<br>* Energy Resonance by Cutaneous Stimulation session<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Evaluation of the reduction in ANXIETY STATE | Evaluation of anxiety before and after RESC session using Spielberger scale | 1 day | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Evaluation of the reduction in ANXIETY STATE | Evaluation of anxiety before and after RESC session using Spielberger scale | 3 days | 
| Evaluation of the reduction in ANXIETY STATE | Evaluation of anxiety before and after RESC session using Spielberger scale | 7 days | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
macrobiopsy, anxiety, Energy Resonance by Cutaneous Stimulation
Effect of Phonophoresis on Trigger Points

Study Overview
=================
Brief Summary
-----------------
purpose of this study was to investigate the effects of phonophoresis with fastum gel versus reparil gel on pain intensity, pain threshold, and cervical ROM of participant with trigger point of upper trapezius.

Detailed Description
-----------------
participants will be divided into 3 groups, 2 study groups and 1 control group.

Official Title
-----------------
Effect of Phonophoresis on Trigger Points

Conditions
-----------------
Trigger Point Pain, Myofascial

Intervention / Treatment
-----------------
* Other: US with fastum
* Other: US with reparil
* Other: US with plain gel


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: upper trapezius trigger point Exclusion Criteria: cervical disc

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 35 Years

Sexes Eligible for Study
-----------------
Female

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Single


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: study Fastum<br>participant in this group will receive US with fastum gel | Other: US with fastum<br>* apply fastum on trigger point with US<br>|
| Experimental: study Reparil<br>participant in this group will receive US with reparil gel | Other: US with reparil<br>* apply reparil on trigger point with US<br>|
| Active Comparator: Control plain gel<br>participant in this group will receive US with gel | Other: US with plain gel<br>* apply gel on trigger point with US<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| pain intensity | change of pain intensity by using VAS from 0 to 10 | Two weeks | 
| pain threshold | change of pain threshold by using PPA | two weeks | 
| ROM | change of ROM by using CROM | two weeks |
Venlafaxine for Postoperative Pain of Laparoscopic Cholecystectomy

Study Overview
=================
Brief Summary
-----------------
Recent studies on the impact of perioperative venlafaxine for treatment of acute postoperative pain have yielded positive outcomes . The aim of the present study is to investigate the role of perioperative venlafaxine on the management of postoperative pain in patients undergoing LC.

Official Title
-----------------
Evaluating Safety and Tolerability of Venlafaxine for Postoperative Pain of Laparoscopic Cholecystectomy

Conditions
-----------------
Laparoscopic Cholecystectomy

Intervention / Treatment
-----------------
* Drug: Venlafaxine
* Drug: Placebo


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: 1. Patients who are scheduled to undergo elective LC Exclusion Criteria: 1- Patients with acute pancreatitis 2. Patients undergoing chronic pain treatment 3. Patients who received analgesics or sedatives 24 h before scheduled surgery 3. Patients had alcohol or drug addiction 4. Severe hepatic and renal dysfunction 5. Previous allergic response to duloxetine 6. Pregnancy and lactation 7. Patients with communication problems, cognitive dysfunction, or psychological disorders

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 75 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Active Comparator: Laparoscopic Cholecystectomy<br> | Drug: Venlafaxine<br>* Patients scheduled for elective LC will receive 150 mg venlafaxine before surgery<br>|
| Placebo Comparator: Control<br> | Drug: Placebo<br>* Patients scheduled for elective LC will receive placebo venlafaxine before surgery<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Change in postoperative pain between the two groups using visual analogue score (VAS) | pain will be assessed using visual analogue score (VAS) 0-100 mm (0 indicated no pain, 100 denoted the most severe pain) pain will be assessed using visual analogue score (VAS) 0-100 mm (0 indicated no pain, 100 denoted the most severe pain) | 24 Hours postoperative | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Postoperative nausea and vomiting (PONV) | will be assessed using PONV scale a 4-point scale: none (0): no nausea, vomiting, and retching; mild (1): happened once; moderate (2): happened 2-3 times; and severe (3): continuous or more than three times. | 24 Hours postoperative |
Nailfold Capillaroscopic Assessment in Pediatric Uveitis Patients

Study Overview
=================
Brief Summary
-----------------
Pediatric uveitis accounts for 5-10% of uveitis cases. it may be infectious or noninfectious in etiology. The etiology of noninfectious uveitis may be autoimmune. The most common causes of pediatric uveitis are idiopathic and juvenile idiopathic arthritis-associated uveitis. Uveitis morbidities in pediatric patients include cataract, glaucoma, and amblyopia. Pediatric uveitis may be accopanied by involvement of the ocular vasculature, such as retinal vasculitis. We hypothesize that there are differences in systemic microcirculation between pediatric uveitis patients and healthy pediatric controls.

Detailed Description
-----------------
The systemic microcirculation will be investigated through nailfold capillaroscopic (NFC) assessment with noninfectious uveitis and healthy pediatric controls. The NFC parameters are: capillary density (number of capillaries per mm), dilated capillaries (apex of >20µm), avascular areas, the presence of microhemorrhages, and capillary morphology (normal, multiple crossings, tortuous, bushy, ramified, non-convex, or bizarre capillaries).

Official Title
-----------------
Nailfold Capillaroscopic Assessment in Pediatric Uveitis Patients

Conditions
-----------------
Uveitis

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: patients with uveitis < 18 years old Exclusion Criteria: infectious uveitis age > 18 years old

Ages Eligible for Study
-----------------
Maximum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| pediatric uveitis<br>pediatric uveitis patients < 18 years old | |
| healthy subjects<br>healthy subjects< 18 years old | |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| capillary density by nailfold capillaroscopy | (number of capillaries per mm) | 6 months | 
| detection of number of dilated capillaries by nailfold capillaroscopy | number of dilated capillaries (apex of >20µm) | 6 months | 
| detection of other abnormalities as avascular areas, microhemorrhages, and abnormal capillary morphology | detection of multiple crossings, tortuous, bushy, ramified, non-convex, or bizarre capillaries | 6 months | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| correlation of nailfold findings with uveitis activity | correlation of capillary abnormalities detected with active uveitis. | 6 months |
Localized Analysis of Normalized Distance From Scalp to Cortex and Personalized Evaluation (LANDSCAPE)

Study Overview
=================
Brief Summary
-----------------
Scalp to cortex distance (SCD), as a key technological parameter of brain stimulation, has been highlighted in the guidelines of non-invasive brain stimulation. However, in the context of age-related brain changes, the region-specific SCD and its impact on stimulation-induced electric field in different types of neurodegenerative diseases remain unclear.

Detailed Description
-----------------
Objective: This study aimed to investigate the region-specific SCD and its relationship with morphometric features and cognitive function in age- and disease-specific populations. Methods: The SCD and cortical thickness (CT) of left primary motor cortex (M1) and dorsolateral prefrontal cortex (DLPFC) were measured in cognitively normal adults and dementia patients. CT-adjusted SCD was used to control the influence of CT on SCD. Head model was developed to simulate the impact of SCD on the electric field induced by transcranial electrical stimulation.

Official Title
-----------------
Localized Analysis of Normalized Distance From Scalp to Cortex and Personalized Evaluation (LANDSCAPE): A Project of MRI-informed Computational Head Model

Conditions
-----------------
Aging, Dementia Alzheimers, Parkinson Disease, Dementia Frontotemporal, Depression in Old Age

Intervention / Treatment
-----------------
* Device: Transcranial Magnetic Stimulation


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Right-handed as assessed by the Edinburgh Inventory Able to attend TMS interventions Consent Independent in daily life activities Exclusion Criteria: Uncorrected visual or auditive deficits not allowing the realization of the test Evolutive disease (such as cancer) Neurological or psychiatric antecedent Counter-indication to MRI

Ages Eligible for Study
-----------------
Minimum Age: 60 Years
Maximum Age: 95 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Neurocognitive disorder (NCD)<br>The NCD patients are defined with a chronological age over 60 years and a Montreal Cognitive Assessment (MoCA) total score between 22 and 26. | Device: Transcranial Magnetic Stimulation<br>* One time for each day, lasting for three weeks.<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Scalp-to-cortex distance will be measured using geometric brain model | Scalp-to-cortex distance (SCD), as a geometric feature, will measured in the Brainsight TMS neuronavigation system. | Baseline | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Aging, Scalp-to-cortex distance, Transcranial brain stimulation, Parkinson disease, Simulation, Predictor